Research News

Created and developed by researchers in the Department of Biomedical Engineering, a wireless, insertable pressure sensor to assist in the diagnosis of urinary incontinence is now one step closer to clinical application. The team is actively recruiting patients for a trial that will begin in early 2020.

“Our vision is to take the monitoring out of the clinic, and to take the catheter out of the monitoring,” said Margot Damaser, PhD, who created and oversees development of the UroMonitor.

Dr. Damaser likens the device to a Fitbit for the bladder. The flexible device, shaped like a coil, is inserted into a patient’s bladder lumen. It tracks physiological data over a four to seven day monitoring period and wirelessly transmits the information to the patient’s electronic medical record to inform diagnosis and clinical management. The patient can then remove the device by a string and dispose of it completely.

Dr. Damaser works closely with urologists—including Howard Goldman, MD, staff in Cleveland Clinic Glickman Urological and Kidney Institute and clinical lead on the study—along with researchers and physicians from Case Western Reserve University and the Louis Stokes Cleveland VA Medical Center.

Dr. Goldman noted that the short-term goal of the trial is to validate whether the UroMonitor demonstrates comparative clinical value to urodynamic testing with equal or greater comfort. The team will insert the device into 8 to 10 patients and monitor their activity in the clinic to determine the safety and efficacy of this diagnostic approach.

If the study shows improved outcomes for patients, the UroMonitor could represent a sea change in urodynamics.

Current diagnostic testing with a catheter is painful and embarrassing for some patients. After the catheter is inserted into the patient’s bladder, they are required to force urination to simulate the issues they face during their daily activities. This simulation may also propagate artifactual data, which is problematic for physicians. The UroMonitor device would counter these issues.

“It’s more comfortable for patients. A clinician inserts it, wirelessly turns it on and sends the patient home. For clinicians, there is more data to confirm the diagnosis and no need for specialized equipment or personnel to administer the test,” said Dr. Damaser.

The device also has the potential to play a therapeutic role for patients with neurogenic etiologies. Possible applications include controlled drug delivery and feedback to neuromodulation or electrical stimulation systems. It may restore sensation for patients with pelvic floor dysfunction or inform them about when to empty their bladder.

On observing urodynamic testing 20 years ago, Dr. Damaser noted, “I thought, ‘Are you kidding?’ We can do so much better.” That continues to be her mantra. With clinical trials set to begin in early 2020, she is already looking ahead to improve the device. She and her team are currently investigating volume sensing capabilities in the lab. “To fully realize a wireless, catheter-free ambulatory urodynamics device, we need to know how much is in the bladder—we need volume,” she said. “So that will be our next step.”

Adapted from Consult QD